Array
(
[a_id] => 435849
[c_id] => 35678
[r_id] => 1744
[rr_id] => 1744
[m_id] => 1
[s_id] => 25646
[id_id] => 0
[v_id] => 50552
[loc_id] => 0
[ft_id] => 0
[a_classification] => news
[a_layout] => 1
[a_headline] => Migraine Cure: FDA Clears Wearable Device For Acute Pain Relief
[a_sheadline] => New Wearable Device Relieves Migraine
[a_slug] => migraine-cure-fda-clears-wearable-device-acute-pain-relief-435849
[a_subheadline] =>
[a_summary] => A new device promises more relief from the pain inflicted by migraines.
[a_article] =>
The first-ever smartphone-controlled wearable for the acute treatment of migraines has been approved for public use by the U.S. Food and Drug Administration (FDA).
The device, named Nerivio Migra, is used for the acute treatment of migraine, with or without aura, in adults who don’t have chronic migraine. Nerivio Migra is a noninvasive neuromodulation device for the relief of acute migraine pain.
This "first-in-category product" is worn on the upper arm and uses smartphone-controlled electronic pulses to relieve migraine through conditioned pain modulation. This is an endogenous analgesic mechanism in which conditioning stimulation inhibits pain in remote body regions.
Nerivio Migra has been found to be as effective as leading devices and drugs in treating acute migraine, but with fewer and milder side effects.
The FDA approved Nerivio Migra based on the results of a randomized, double-blind, placebo-controlled study involving 252 patients that had two to eight migraines per month.
Participants who used the wearable reported more pain relief than those who used a placebo (66.7 percent against 38.8 percent). They also reported more freedom from pain (37.4 percent vs. 18.4 percent) and relief of the most bothersome symptoms (46.3 percent vs. 22.2 percent) only two hours after treatment.
The study said pain relief lasted some 48 hours after treatment. The rate of device-related harmful events was low and was similar between treatment groups (4.8 percent vs. 2.4 percent).
Theranica, the maker of Nerivio Migra, said device‐related side effects included a sensation of warmth, temporary arm/hand numbness, redness, itching, tingling, muscle spasm and pain in the arm, shoulders, or neck. All were mild and resolved within 24 hours. They did not require medical treatment.
"[The device] can provide patients with significant relief of pain and other migraine symptoms without the side effects presented by drugs," said neuroscientist Messoud Ashina, M.D., Ph.D., of the Danish Headache Center. Dr. Ashina is also president-elect of the International Headache Society,.
Theranica plans to launch Nerivio Migra in the United States this year "at an affordable price."
"We have identified at least 7 different painful conditions that may be relieved by this noninvasive, drug-free technology after appropriate clinical development,” said Alon Ironi, CEO and co-founder of Theranica.
Migraine is reportedly the third most common disease in the world. It has an estimated global prevalence of 14.7 percent of the world’s population.
The first-ever smartphone-controlled wearable for the acute treatment of migraines has been approved for public use by the U.S. Food and Drug Administration (FDA).
The device, named Nerivio Migra, is used for the acute treatment of migraine, with or without aura, in adults who don’t have chronic migraine. Nerivio Migra is a noninvasive neuromodulation device for the relief of acute migraine pain.
This "first-in-category product" is worn on the upper arm and uses smartphone-controlled electronic pulses to relieve migraine through conditioned pain modulation. This is an endogenous analgesic mechanism in which conditioning stimulation inhibits pain in remote body regions.
Nerivio Migra has been found to be as effective as leading devices and drugs in treating acute migraine, but with fewer and milder side effects.
The FDA approved Nerivio Migra based on the results of a randomized, double-blind, placebo-controlled study involving 252 patients that had two to eight migraines per month.
Participants who used the wearable reported more pain relief than those who used a placebo (66.7 percent against 38.8 percent). They also reported more freedom from pain (37.4 percent vs. 18.4 percent) and relief of the most bothersome symptoms (46.3 percent vs. 22.2 percent) only two hours after treatment.
The study said pain relief lasted some 48 hours after treatment. The rate of device-related harmful events was low and was similar between treatment groups (4.8 percent vs. 2.4 percent).
Theranica, the maker of Nerivio Migra, said device‐related side effects included a sensation of warmth, temporary arm/hand numbness, redness, itching, tingling, muscle spasm and pain in the arm, shoulders, or neck. All were mild and resolved within 24 hours. They did not require medical treatment.
"[The device] can provide patients with significant relief of pain and other migraine symptoms without the side effects presented by drugs," said neuroscientist Messoud Ashina, M.D., Ph.D., of the Danish Headache Center. Dr. Ashina is also president-elect of the International Headache Society,.
Theranica plans to launch Nerivio Migra in the United States this year "at an affordable price."
"We have identified at least 7 different painful conditions that may be relieved by this noninvasive, drug-free technology after appropriate clinical development,” said Alon Ironi, CEO and co-founder of Theranica.
Migraine is reportedly the third most common disease in the world. It has an estimated global prevalence of 14.7 percent of the world’s population.
Migraines or recurrent headaches can cause severe pain, sensitivity to light and nausea. Hermes Rivera/Unsplash
The study also revealed that individuals who quit smoking, regardless of age, can achieve a life expectancy similar to non-smokers within approximately 10 years after quitting, and nearly half of this benefit can be noticed within just three years.
Researchers found that a combination of genetics and environmental factors reduces longevity in dementia patients. The same combination may shorten the lives of their siblings even without dementia.
The suicide rates increase substantially when air pollution rises, and the effect was particularly strong in the elderly, with older women 2.5 times more at risk than other groups.
While mental stress is commonly acknowledged in connection with grief, it is crucial to understand that grief can also present physical symptoms, including illnesses, fatigue, pain, and sleep disturbances.
The use of antidepressants, particularly fluoxetine, could affect the development of the prefrontal cortex of the infant's brain, potentially raising the risk of mental health disorders later in their life.
Researchers have developed smart earrings that could continuously monitor a person's earlobe temperature. The innovation known as Thermal Earring could also be potentially used to track signs of ovulation, stress, eating, and exercise.
The researchers made the interesting finding using a trial involving patients with a rare genetic condition called Alpha-1 antitrypsin deficiency (AATD).
People infected with the flu were more likely to need hospital care in the following year for common neurologic conditions than people who had the SARS-CoV2 infection.
Among women with a history of pregnancy complications, those who achieved or maintained high heart health after pregnancy were at a similar risk for heart disease as women without adverse pregnancy outcomes and good cardiovascular health, the study stated.
The study published in the journal BMJ indicated that individuals with hypermobile joints had a 30% higher chance of not fully recovering from COVID-19 and experiencing persistent fatigue associated with long COVID.
The studies showed that COVID antigens lingered in the blood up to 14 months after infection and more than two years in tissue samples of people who had the infection.
Those individuals who receive a COVID-19 vaccine during the first half of their menstrual cycle are more likely to experience cycle length changes than those receiving a vaccine in the latter half.
The first-ever smartphone-controlled wearable for the acute treatment of migraines has been approved for public use by the U.S. Food and Drug Administration (FDA).
The device, named Nerivio Migra, is used for the acute treatment of migraine, with or without aura, in adults who don’t have chronic migraine. Nerivio Migra is a noninvasive neuromodulation device for the relief of acute migraine pain.
This "first-in-category product" is worn on the upper arm and uses smartphone-controlled electronic pulses to relieve migraine through conditioned pain modulation. This is an endogenous analgesic mechanism in which conditioning stimulation inhibits pain in remote body regions.
Nerivio Migra has been found to be as effective as leading devices and drugs in treating acute migraine, but with fewer and milder side effects.
The FDA approved Nerivio Migra based on the results of a randomized, double-blind, placebo-controlled study involving 252 patients that had two to eight migraines per month.
Participants who used the wearable reported more pain relief than those who used a placebo (66.7 percent against 38.8 percent). They also reported more freedom from pain (37.4 percent vs. 18.4 percent) and relief of the most bothersome symptoms (46.3 percent vs. 22.2 percent) only two hours after treatment.
The study said pain relief lasted some 48 hours after treatment. The rate of device-related harmful events was low and was similar between treatment groups (4.8 percent vs. 2.4 percent).
Theranica, the maker of Nerivio Migra, said device‐related side effects included a sensation of warmth, temporary arm/hand numbness, redness, itching, tingling, muscle spasm and pain in the arm, shoulders, or neck. All were mild and resolved within 24 hours. They did not require medical treatment.
"[The device] can provide patients with significant relief of pain and other migraine symptoms without the side effects presented by drugs," said neuroscientist Messoud Ashina, M.D., Ph.D., of the Danish Headache Center. Dr. Ashina is also president-elect of the International Headache Society,.
Theranica plans to launch Nerivio Migra in the United States this year "at an affordable price."
"We have identified at least 7 different painful conditions that may be relieved by this noninvasive, drug-free technology after appropriate clinical development,” said Alon Ironi, CEO and co-founder of Theranica.
Migraine is reportedly the third most common disease in the world. It has an estimated global prevalence of 14.7 percent of the world’s population.
Migraines or recurrent headaches can cause severe pain, sensitivity to light and nausea. Hermes Rivera/Unsplash
